To establish a method to non-invasively monitor BRAF silencing within the context of a tumor model in vivo, a LOX-IMV1 melanoma line with the pHUSH-Braf-shRNA [26] was re-engineered to express a Luc-BRAF transcript fusion. The gene discussed is BRAF; the disease is melanoma.